Oral Drug Delivery News

  1. Pharmanovia Partnership To Breathe New Life Into Iconic Medicines 7/14/2022

    Nanoparticles offer the possibility for increased efficacy in existing pharmaceuticals and enhanced bioavailability. Learn more about the potential for API optimization using nanoforming technologies.

  2. Catalent And Migvax Sign Agreement To Develop An Orally Disintegrating Freeze-Dried Tablet Vaccine Against COVID-19 6/7/2022

    Catalent, the global leader in enabling biopharma, cell, gene, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, and MigVax, an Israeli biopharmaceutical company developing an oral subunit vaccine against COVID-19, today announced that they have signed a development agreement to leverage Catalent’s proprietary Zydis Bio orally disintegrating tablet (ODT) technology for delivering the MigVax-101 vaccine

  3. Lonza Completes Dedicated Early Clinical Phase Development And Manufacturing Facility In Bend (OR) 6/1/2022

    Lonza has enhanced its offering for customers in the early phases of their clinical trials by adding a dedicated Early Phase Clinical Manufacturing facility at its Small Molecules site in Bend, Oregon.

  4. Societal CDMO Signs Three-Year Manufacturing And Supply Agreement With InfectoPharm For Ritalin LA In Europe 5/5/2022

    Societal CDMO, Inc., a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that it has entered into a three-year manufacturing and supply agreement with InfectoPharm for Ritalin LA capsules (methylphenidate hydrochloride extended-release capsules) in Europe.

  5. Societal CDMO Signs Three-Year Manufacturing And Supply Agreement With InfectoPharm For Ritalin LA® In Europe 5/5/2022

    Societal CDMO, Inc. (“Societal CDMO” or “Societal”; NASD: SCTL), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that it has entered into a three-year manufacturing and supply agreement with InfectoPharm for Ritalin LA® capsules (methylphenidate hydrochloride extended-release capsules) in Europe